4D Molecular Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2021
Filed with the SEC on May 13, 2021 and accepted by EDGAR at May 13, 2021, 20:21 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-01-01 to 2021-03-31 | $2.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2021-01-01 to 2021-03-31 | $12.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-01-01 to 2021-03-31 | −$16.3m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2021-01-01 to 2021-03-31 | −$16.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-01-01 to 2021-03-31 | −$0.61 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months2021-01-01 to 2021-03-31 | −$15.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2021-01-01 to 2021-03-31 | $642.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-03-31 | $259.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-03-31 | $264.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-03-31 | $270.1m | us-gaap:Assets |
| Current liabilities | At period end2021-03-31 | $13.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-03-31 | $27.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-03-31 | $242.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-21-027576. Last ingested by Listed: Oct 24, 2026, 15:14 ET. Listed shows no prices and gives no investment advice.